RxDoctor Payments Data

Timothy Tsoi, MD

Cardiovascular Disease · Fremont, CANPI 1982765327

Payments from drug & device makers

$32,299in general payments, 2019–2025

Across 122 payments — averaging $264.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$28K
  • Atricure, Inc.$2K
  • AstraZeneca$343
  • Johnson & Johnson$182
  • Merck$148
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$148
  • plus $893 from 9 others

What the payments were for

  • Speaking & faculty fees$20,62564%
  • Travel & lodging$4,40214%
  • Food & beverage$7,02822%
  • Education$2431%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,299 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$155,652
Medicare patients
949
Services billed
2,176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban226$256,036
MultaqDronedarone Hcl35$57,270
BrilintaTicagrelor21$24,422
XareltoRivaroxaban13$20,918
EntrestoSacubitril/Valsartan12$11,261
Propafenone Hcl90$10,330
Atorvastatin Calcium243$2,967
Carvedilol271$2,723
Diltiazem 24hr Er (Cd)Diltiazem Hcl67$2,429
Valsartan55$2,312
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide16$2,304
Potassium Chloride70$2,019
ClopidogrelClopidogrel Bisulfate94$2,005
Hydralazine Hcl46$1,891
Doxazosin Mesylate63$1,849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$93$256,036226 claims
AstraZenecaBrilinta$343$24,42221 claims
Johnson & JohnsonXarelto$182$20,91813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Fremont

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →